Has Maribonn Tiangson received payments from drug or device companies?

Yes. Drug and device makers reported $2,241 in general payments to Maribonn Tiangson across 129 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Maribonn Tiangson did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Maribonn Tiangson come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Maribonn Tiangson

Internal Medicine · Vancouver, WANPI 1982157996

Payments from drug & device makers

$2,241in general payments, 2019–2025

Across 129 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$578
Lilly USA, LLC$301
Esperion Therapeutics, Inc.$195
Novartis$178
Novo Nordisk$167
Pfizer$146
plus $674 from 13 others

What the payments were for

Food & beverage$2,241100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	33	$578
Lilly USA, LLC	21	$301
Esperion Therapeutics, Inc.	11	$195
Novartis	9	$178
Novo Nordisk	11	$167
Pfizer	7	$146
Bayer	4	$142
Takeda Pharmaceuticals U.S.A., Inc.	7	$124
GSK	7	$90
Biohaven Pharmaceutical Holding Company Ltd.	3	$62
Biohaven Pharmaceuticals, Inc.	3	$42
Astellas Pharma US Inc	2	$40
Amgen(2 entities)	2	$37
Johnson & Johnson	2	$36
AstraZeneca	2	$30
IBSA Pharma Inc.	2	$25
Sanofi-aventis U.S. LLC	1	$17
Gilead	1	$15
Kowa Pharmaceuticals America, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Kerendia$104

How this compares

$2,241 in reported general payments places this provider in the 90th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	58	$42,943
Spiriva RespimatTiotropium Bromide	30	$21,323
JardianceEmpagliflozin	32	$14,688
PradaxaDabigatran Etexilate Mesylate	59	$12,311
Liraglutide	13	$8,797
Humulin NInsulin Nph Human Isophane	30	$6,839
Wixela InhubFluticasone Propion/Salmeterol	23	$5,834
Levothyroxine Sodium	165	$2,901
Atorvastatin Calcium	228	$2,575
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	136	$2,436
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm	20	$2,193
Insulin Glargine-Yfgn	15	$2,138
Albuterol Sulfate HfaAlbuterol Sulfate	88	$2,129
Losartan Potassium	150	$1,910
Gabapentin	108	$1,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic	$167	$42,94358 claims
Lilly USA, LLCHumulin N, Humulin 70-30	$301	$9,03250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Vancouver

Sabrina BenjaminOlympia$7.9M
Ryan AhernSeattle$7.3M
Eric KleinOlympia$2.4M
Scott RamseySeattle$2M
Vidya MenonTacoma$1.8M
Peter ShalitSeattle$1.8M
Yuan Po TuEverett$1.6M
Peiqing QianSeattle$1.5M
Radica AlicicSpokane$1.5M
Shelly KhuranaLynnwood$1.3M

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →